Cargando…

Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

Agomelatine (AGM) was approved for the treatment of major depressive disorder (MDD) in adults by the European Medicines Agency (EMA) in February 2009. It is an analogue of melatonin and features a unique pharmacodynamic profile with agonism on both types of melatonergic receptors (MT1/MT2) and antag...

Descripción completa

Detalles Bibliográficos
Autor principal:	Gahr, Maximilian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243030/ https://www.ncbi.nlm.nih.gov/pubmed/25426008 http://dx.doi.org/10.2174/1570159X12999140619122914

Ejemplares similares

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder
por: Huang, Juan, et al.
Publicado: (2023)

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
por: Maniadakis, Nikos, et al.
Publicado: (2013)

Efficacy and tolerability of agomelatine in the treatment of depression
por: Plesničar, Blanka Kores
Publicado: (2014)

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
por: Stein, Dan J.
Publicado: (2023)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak, Jan, et al.
Publicado: (2013)

Agomelatine for postpartum depression and breastfeeding
por: Xiao, Le
Publicado: (2021)

Agomelatine: The evidence for its place in the treatment of depression
por: Eser, Daniela, et al.
Publicado: (2010)

Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
por: De Berardis, Domenico, et al.
Publicado: (2015)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?
por: Potměšil, Petr
Publicado: (2019)

Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study
por: Ivanov, Stanislav V, et al.
Publicado: (2014)

Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis
por: Guo, Yue-Han, et al.
Publicado: (2023)

Agomelatine and its therapeutic potential in the depressed patient
por: Kennedy, Sidney H, et al.
Publicado: (2007)

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine
por: Li, Zhe, et al.
Publicado: (2023)

Is Agomelatine Associated with Less Sedative-Hypnotic Usage in Patients with Major Depressive Disorder? A Nationwide, Population-Based Study
por: Hsing, Shih-Chun, et al.
Publicado: (2020)

Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2020)

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Howland, Robert H
Publicado: (2009)

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
por: Levitan, Michelle Nigri, et al.
Publicado: (2015)

Agomelatine: relief ensured at each and every stage of depression
por: Möller, Hans-Jurgen
Publicado: (2010)

Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders
por: Savino, Rosa, et al.
Publicado: (2023)

Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action
por: Millan, Mark J.
Publicado: (2022)

Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease
por: Su, Qiang, et al.
Publicado: (2022)

Agomelatine Softens Depressive-Like Behavior through the Regulation of Autophagy and Apoptosis
por: Chen, Fengpei, et al.
Publicado: (2021)

Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine
por: Stein, Dan J.
Publicado: (2021)

A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study
por: Urade, Chetan S., et al.
Publicado: (2015)

A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD)
por: Guo, Ping, et al.
Publicado: (2023)

Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms
por: Martinotti, Giovanni, et al.
Publicado: (2016)

Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?
por: Zhu, Yuncheng, et al.
Publicado: (2023)

Acute Hepatitis Due to Agomelatine Use in Elderly Women with Depression: Case Series
por: Chang, Cheng-Chen, et al.
Publicado: (2021)

Successful Treatment with Agomelatine in NES: A Series of Five Cases
por: Milano, W., et al.
Publicado: (2013)

Agomelatine: A novel melatonergic antidepressant
por: Manikandan, S
Publicado: (2010)

Agomelatine Efficacy in the Night Eating Syndrome
por: Milano, Walter, et al.
Publicado: (2013)

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
por: Fornaro, Michele, et al.
Publicado: (2013)

Agomelatine Augmentation of Escitalopram Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report
por: De Berardis, Domenico, et al.
Publicado: (2012)

The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia
por: Wang, Carol Sheei-Meei, et al.
Publicado: (2022)

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
por: Chen, Jian-wei, et al.
Publicado: (2018)

Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors
por: Signorelli, Maria S, et al.
Publicado: (2014)

The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice
por: De Berardis, Domenico, et al.
Publicado: (2013)

The Effects of Agomelatine Treatment on Lipopolysaccharide-Induced Septic Lung Injuries in Rats
por: Köse, Duygu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eept1d33sf87h5p6l8oau7fvt9